- Home
- OGEN vs ONCT Comparison
OGEN vs ONCT Comparison
Compare OGEN & ONCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OGEN
- ONCT
- Stock Information
- Founded
- OGEN 1996
- ONCT N/A
- Country
- OGEN United States
- ONCT United States
- Employees
- OGEN N/A
- ONCT N/A
- Industry
- OGEN Biotechnology: Pharmaceutical Preparations
- ONCT Biotechnology: Pharmaceutical Preparations
- Sector
- OGEN Health Care
- ONCT Health Care
- Exchange
- OGEN Nasdaq
- ONCT Nasdaq
- Market Cap
- OGEN 4.5M
- ONCT 4.3M
- IPO Year
- OGEN N/A
- ONCT N/A
- Fundamental
- Price
- OGEN $0.32
- ONCT $1.13
- Analyst Decision
- OGEN
- ONCT Buy
- Analyst Count
- OGEN 0
- ONCT 3
- Target Price
- OGEN N/A
- ONCT $10.00
- AVG Volume (30 Days)
- OGEN 738.8K
- ONCT 157.5K
- Earning Date
- OGEN 11-13-2024
- ONCT 11-06-2024
- Dividend Yield
- OGEN N/A
- ONCT N/A
- EPS Growth
- OGEN N/A
- ONCT N/A
- EPS
- OGEN N/A
- ONCT N/A
- Revenue
- OGEN N/A
- ONCT $2,161,000.00
- Revenue This Year
- OGEN N/A
- ONCT $113.76
- Revenue Next Year
- OGEN N/A
- ONCT N/A
- P/E Ratio
- OGEN N/A
- ONCT N/A
- Revenue Growth
- OGEN N/A
- ONCT 227.92
- 52 Week Low
- OGEN $0.28
- ONCT $1.03
- 52 Week High
- OGEN $7.74
- ONCT $13.20
- Technical
- Relative Strength Index (RSI)
- OGEN 41.16
- ONCT 37.09
- Support Level
- OGEN $0.30
- ONCT $1.03
- Resistance Level
- OGEN $0.43
- ONCT $1.30
- Average True Range (ATR)
- OGEN 0.03
- ONCT 0.19
- MACD
- OGEN 0.01
- ONCT -0.01
- Stochastic Oscillator
- OGEN 23.47
- ONCT 13.70
About OGEN Oragenics Inc.
Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's lead product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification.
About ONCT Oncternal Therapeutics Inc.
Oncternal Therapeutics Inc is a clinical-stage oncology company developing first-in-class, novel therapies that target a broad spectrum of cancers with a large unmet medical need. The Company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to ROR1 (Receptor-tyrosine kinase-like Orphan Receptor 1), and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoprotein. The Company is also developing ONCT-808, a CAR-T (chimeric antigen receptor T-cells) product candidate that target ROR1, and ONCT-534, a dual-action androgen receptor inhibitor product candidate for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. The Company has one operating segment in the United States.